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In the article entitled “A method to identify trace sulphated IgG
N-glycans as biomarkers for rheumatoid arthritis”, Wang et al.
reported an analysis of glycans in 277 patients with rheumatoid
arthritis (RA) and 141 healthy individuals1. The analytical
method they used was very sensitive and powerful, providing
results for glycans that represented only 0.005% of the glycome.
They identified a total of 444 glycan structures and concluded
that all these structures are N-glycans that are attached to
immunoglobulin G (IgG). However, this glycomic analysis of IgG
obtained by protein A purification does not account for the
ubiquitous presence of varying levels of other contaminating
plasma glycoproteins. As experimental evidence for association of
these trace glycans with IgG was not provided, we believe that
many of these glycans actually originated from other plasma
glycoproteins, and not IgG.
In the past few years we have analysed the glycome composi-
tion of more than 50,000 samples from different clinical and
epidemiological studies2–13. The quality assurance measures we
took enabled us to reliably determine sources of experimental
variation and levels of experimental error in glycomic experi-
ments. From these analyses we learned that one of the major
sources of error in IgG glycome analysis is linked to glycoprotein
contaminants. Affinity purification of IgG using proteins A or G
is never absolute and varying levels of contaminating plasma
proteins are always present. As most plasma proteins are glyco-
sylated, variations in levels of contaminating proteins can have
substantial effect on the apparent IgG glycome composition. For
example, the diantennary, digalactosylated and disialylated glycan
without core fucose (H5N4S2, or A2G2S2 in alternative
nomenclature) is the most prevalent glycan on total plasma
proteins, while it is present in very low amounts in the total IgG
glycome (Fig. 1a–c), and practically nonexistent on IgG Fc3,11,12.
When released IgG glycans are analysed, even with very low
levels of contaminating plasma proteins (not even visible on
Coomassie-stained SDS-PAGE), the majority of H5N4S2 glycans
in the “IgG glycome” actually originate from other plasma pro-
teins such as transferrin, and not IgG14. Wang et al.1 reported
that, in their study, two H5N4S2 isomers had a combined relative
abundance of 5.4% (Supplementary Table 4). In our high-
throughput studies of released IgG glycans (on over 30,000
individuals) this structure was less than 1% in nearly all samples.
Both ultra-high performance liquid chromatography (UHPLC)
and matrix-assisted laser desorption/ionization-time of flight-
mass spectrometry (MALDI-TOF-MS) analyses resulted in
comparable levels of this glycan (Fig. 1b, c)6,7,15. This structure
was slightly elevated in patients with RA, mostly originating from
glycans attached to Fab, but still below 1.5% of the total IgG
glycome (Fig. 1c).
We consider that high levels of H5N4S2 are an indicator of
contamination with other glycoproteins and use it for quality
assessment of IgG purification. The fact that the H5N4S2 glycan
represents over 5% of the IgG glycome in the study of Wang
et al.1 indicates that the purified IgG may contain substantial
levels of contaminating plasma glycoproteins. Furthermore, this
glycan had a particularly high standard deviation, again sug-
gesting that it was mainly derived from varying levels of con-
taminating plasma glycoproteins. The study by Wang et al.1 may
therefore be confounded by sample purity issues, and the claim
that the novel glycans are linked to IgG seems insufficiently
supported. To the contrary, many of these low-abundance glycan
structures may be derived from contaminating plasma proteins,
and not or only to a lesser extent from IgG.
Figure 3 of Wang et al.1 implies that the novel glycan structures
are actually Fc glycans, which may be questioned as the human
IgG glycome is composed of glycans from the Fc as well as the
Fab portion of the molecule. A state-of-the-art method of con-
firming IgG as the carrier molecule of the glycans and revealing
the attachment site in the Fc portion of the molecule would be a
complementary glycopeptide analysis. In the study by Wang
et al.1 this was not performed and therefore the claim that IgG is
the carrier of the 444 different N-glycan structures is not sub-
stantiated with experimental evidence.
We do not imply that any of the experimental data presented
in the manuscript are false, or that association with rheumatoid
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Fig. 1 IgG and total plasma N-glycomes. a An overlay of UHPLC traces of IgG (red) and total plasma (black) glycomes. Major structures that are present in
both total plasma and IgG glycomes are presented as cartoons composed of N-acetylglucosamine (blue square), mannose (green circle), galactose (yellow
circle), fucose (red triangle) and sialic acid (purple diamond). The red arrow marks the largest plasma glycan peak that contains the diantennary,
digalactosylated and disialylated glycan without core fucose (H5N4S2). This structure is present only in trace amounts in the total IgG glycome pool and is
completely undetectable as a corresponding Fc glycopeptide3,11,12. b Composition of the total plasma and IgG N-glycomes in 2611 individuals from the
general population analysed by UHPLC5. c Comparison of major IgG glycan structures in 31 patients with RA and 25 age-matched healthy individuals
measured by MALDI-TOF-MS15
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arthritis is unsubstantiated. However, we challenge the conclusion
that the analysed glycans originate from IgG, as this claim is not
substantiated by the experimental evidence.
Methods
UHPLC analysis of IgG and total plasma N-glycome was performed on 2611
individuals as described previously5,6. Briefly, IgG was isolated by affinity chro-
matography on protein G. N-glycans from isolated IgG and from plasma samples
were released with PNGase F, labelled with 2-aminobenzamide and analysed by
UHPLC. IgG N-glycan chromatograms were separated into 24 and total plasma N-
glycan chromatograms into 39 glycan peaks. The content of each glycan peak had
been determined previously by MS and exoglycosidase digestion.
MS analysis of IgG N-glycome in 31 patients with RA and 25 age-matched
healthy individuals was performed as described previously15. Briefly, IgG was
isolated by affinity chromatography on CaptureSelect IgG-Fc (Hu) beads. N-
glycans from isolated IgG were released with PNGase F, ethyl esterification was
performed to prevent the loss of sialic acids, and released glycans were analysed by
MALDI-TOF-MS.
Data availability. All relevant data are available from the corresponding author
upon reasonable request.
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